Revelation Biosciences (REVB)
(Delayed Data from NSDQ)
$1.84 USD
-0.22 (-10.68%)
Updated May 13, 2024 03:59 PM ET
After-Market: $1.84 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
REVB 1.84 -0.22(-10.68%)
Will REVB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for REVB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REVB
Bears are Losing Control Over Revelation Biosciences, Inc. (REVB), Here's Why It's a 'Buy' Now
REVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for REVB
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
Revelation Biosciences GAAP EPS of -$2.46
Revelation Biosciences reports Q1 EPS ($2.46), consensus ($5.38)
Revolution Beauty Discloses Total Voting Rights
Revolution Beauty Group’s Stake Shift to UBS